Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

FORGOTTEN HISTORY: Alnylam pharmaceuticals - The Untold Story

‘Important moment’ as at-home heart treatment approved for NHS use

About 1,500 patients in England and Wales live with the rare heart condition

The Independent UK

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

Benzinga

Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) stock is trading lower after the company reported third-quarter earnings.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Profits May Be Just Around the Corner for This Strong-Buy Pharma Stock

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ALNY has a 100% technical “Buy” opinion via Barchart. The company boasts a robust pipeline, recent FDA approvals, and dramatic projected revenue and earnings growth for 2025. Analyst sentiment is mostly bullish with high price targets....

Barchart

This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday.

Benzinga

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) continue to outperform market expectations. Amid a backdrop of growing demand for innovative treatments, Alnylam’s recent performance highlights the company’s strong position in the competitive landscape.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Benzinga

New therapy for Huntington’s disease ‘may slow progression’

There are thought to be around 7,000 people living with Huntington’s disease in the UK.

Evening Standard

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga

Where Alnylam Pharmaceuticals Stands With Analysts

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022

Upgrades

Benzinga

Alnylam's Stock Gains Following FDA Nod For hATTR Amyloidosis Candidate

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ (NASDAQ: ALNY) lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

Upgrades

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Analyst Ratings for Alnylam Pharmaceuticals

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

Benzinga

Alnylam Pharmaceuticals Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Alnylam Pharmaceuticals's (NASDAQ:ALNY) reported sales totaled $213.26 million. Despite a 7.01% increase in earnings, the company posted a loss of $240.34 million.

Benzinga

Expert Ratings for Alnylam Pharmaceuticals

Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Recap: Alnylam Pharmaceuticals Q1 Earnings

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q1 earnings results on Thursday, April 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What To Know About Morgan Stanley's Downgrade of Alnylam Pharmaceuticals

Morgan Stanley downgraded its rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) to Equal-Weight with a price target of $178.00, changing its price target from $210.00 to $178.00. Shares of Alnylam Pharmaceuticals are trading down 4.47% over the last 24 hours, at $159.53 per share.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Benzinga

Alnylam Pharmaceuticals Q1 2022 Earnings Conference Call On April 28, 2022 At 08:30 AM ET

Alnylam Pharmaceuticals (NASDAQ:ALNY) will host a conference call at 08:30 AM ET on April 28, 2022, to discuss Q1 2022 earnings results.

Benzinga

Analyst Ratings for Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:

Benzinga

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Benzinga

What 8 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Benzinga

Looking Into Alnylam Pharmaceuticals's Return On Capital Employed

Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q4 sales of $258.54 million. Earnings fell to a loss of $258.46 million, resulting in a 26.38% decrease from last quarter.

1 2

People

Stéphane Bancel

22 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.